Professor Whelan is a highly experienced clinician and researcher, having spent nearly 30 years studying the treatment of sarcomas and managing cancer in teenagers and young adults. He is a Consultant Medical Oncologist and Lead at one of the largest sarcoma services in Europe in the University College London Hospital. He is a Professor of Cancer Medicine at UCL and is co-chair of the Sarcoma Advisory Group of the London and South East Sarcoma Network, which serves a population of approximately 15 million people.

Professor Whelan major programmes in young people’s cancer and sarcoma. He established and co-ordinated the EUROEWING Consortium ( and has served on the boards of the Connective Tissue Oncology Society and the European Musculoskeletal Oncology Society. He chaired the National Cancer Research Institute Teenage and Young Adult Clinical Studies Group for nine years, and was a long standing member of the Sarcoma Clinical Studies Group, of which he continues to be an active member of its bone sarcoma sub group.

Professor Whelan is a member of the NHS England Cancer Surgery Clinical Reference Group, and leads on providing expert clinical guidance for specialised commissioning of sarcoma services.

Professor Beggs is the founder of the Beggs Lab and Reader in Cancer Genetics & Surgery in the Institute of Cancer and Genomic Sciences at the University of Birmingham, as well as the Consultant Colorectal & General Surgeon at the Queen Elizabeth Hospital, Birmingham.

He is part of the West Midlands multi-disciplinary team delivering the pelvic exenteration service and is a member of the National Cancer Research Institute (NCRI) Colorectal Cancer Clinical Support Group (CSG).

Professor Beggs has a special interest in the multi-omic profiling of cancers, in particular, colorectal, oesophageal and sarcoma and the Beggs Lab is part of the Human Model Cancers Initiative. 

He is a member of the Human Cancer Models Initiative, and a member of the consortium that sequenced the reference human genome.

Dr Behjati is a Group Leader at the Wellcome Sanger Institute and Consultant Paediatric Oncologist at Addenbrooke’s Hospital, Cambridge. His research is focused on unravelling the origins of cancer, using a variety of cutting edge nucleic acid sequencing technologies. Previously he has defined the somatic genetic basis of different subtypes of sarcoma, as part of the UK contribution to the International Cancer Genome Consortium. He continues to pursue his interest in sarcoma genomics through the Genomics England sarcoma programme and his own research. Dr Behjati read medicine at the University of Oxford and pursued clinical academic training in paediatric oncology in London and Cambridge.

Professor Brennan is a Consultant Paediatric Oncologist and Honorary Senior Lecturer at the Royal Manchester Children’s Hospital, with over 30 years as a qualified doctor, as well as further training in General Paediatrics, Paediatric and Adolescent Oncology and an MD in the late effects of Childhood Leukaemia.

She also has extensive experience in sarcoma as the Clinical Lead on the European paediatric Soft tissue sarcoma Study Group (EPSSG), the non-rhabdyomyosarcoma soft tissue sarcomas study for the UK (NRSTS) and Internataional/UK Euro Ewing 2012 Study and as a member of the Euro Ewing Consortium.

Bernadette is also a member of the Sarcoma Clinical Studies Group, the Children’s Cancer and Leukaemia Group (CCLG), the Rare Tumour Group, the EXPeRT European Rare Tumour Group and chairs the Young Onset Soft-Tissue Sarcoma (YOSS) subgroup.

Professor Burchill is the Professor of Adolescent and Paediatric Cancer Research at the University of Leeds and scientific director of the Children’s Cancer Research Group at St James’s University Hospital, the translational research laboratory she established in 1992. Her research focuses on drug refractory and metastatic tumour cells which are frequently responsible for progression and relapse. With a passion to translate scientific knowledge internationally into clinical practice, she is chair of research in the European EWING Cooperative (EEC), the Society International of Oncology Paediatric-Neuroblastoma (SIOPEN) Molecular Monitoring Group and co-chair of the International Neuroblastoma Response Criteria Bone Marrow Working Group (INRC BMWG).

Sue is also a member of the NCRI Sarcoma Clinical Studies Group, NCRI Bone Sarcoma subgroup and NCRI CCL Neuroblastoma Clinical Studies Group. She continues to inspire young scientists and clinicians by supervising undergraduate and postgraduate students.

Dr Campbell Hewson has been a Consultant Paediatric Oncologist at the Great North Children’s Hospital in Newcastle upon Tyne since 2003. He specialises in Solid Tumours, Early Phase Trials and Palliative care.

As a strong advocate for new therapies he jointly established a Northern Network for Children’s Cancer Early Phase trials –the ”INCLuDE” network- which encompasses Northern England, Scotland and Northern Ireland. This network has been the template for the networks which now cover the whole UK.

He is active as a member of the UK Experimental Medicines Cancer Group Paediatric Network Strategy group and the European Innovative Therapies for Children’s Cancer consortium.

He is the Specialty Group lead for Children’s Research NIHR CRN North east and North Cumbria, leads children’s clinical research for Newcastle upon Tyne as well as Children’s Cancer Theme lead for the NIHR CYPMed Tech Cooperative.

He is Principal Investigator for a number of late and early phase studies for sarcomas and a member of the NCRI Sarcoma clinical Study group.

Dr Carter is a Clinical Senior Lecturer in Experimental Cancer Medicine at the University of Manchester.  She is also an Honorary Consultant in Medical Oncology at the Christie NHS Foundation trust.

She is the principal investigator on a portfolio of early phase clinical trials in the Experimental Cancer Medicine Team. In her research she focuses on the development of early phase clinical trials for new anti-cancer treatments and translational assays.  She also researches the role of supportive care treatments for clinical trial patients. 

She is a member of the National Cancer Research Institute Sarcoma Clinical Studies Group.

Prof Cool is a Consultant Orthopaedic and Oncological Surgeon at The Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust, as well as an Honorary Senior Lecturer at the University of Manchester.

Paul has specialist interests in soft tissue and bone sarcoma, and tumour-like conditions.

With an undergraduate at Queen’s College, Cambridge and the Royal Free Hospital, London followed by an MD in oesophageal cancer at the University of Birmingham and Fellowships across Europe, Mr Desai was appointed as the Consultant Surgeon at the Midlands Abdominal and Retroperitoneal Sarcoma Unit in 2011.

Anant is on the editorial advisory board for the European Journal of Surgical Oncology, the Chair of the West Midlands Sarcoma Advisory Group and leader of the regional soft tissue sarcoma multi-disciplinary team. He has extensive experience of research and contributes to a number of Journals as a reviewer. He is an active member of the NCRI Sarcoma Research Group

Consultant Orthopaedic Surgeon and Cancer Lead, Royal National Orthopaedic Hospital, Stanmore

Consultant Orthopaedic Surgeon and Cancer Lead, Royal National Orthopaedic Hospital, Stanmore

Mr Gerrand began as a Consultant Orthopaedic Surgeon and Clinical lead for Cancer at the Royal National Orthopaedic Hospital in 2018, having previously worked for the Newcastle Upon Tyne Hospital NHS Foundation Trust for 17 years. With a research interest in surgical aspects of sarcoma care and innovation in the NHS, he specialises in the management of patients with bone and soft tissue tumours, including bone and soft tissue sarcomas.

Craig is a Board member of the British Sarcoma Group and sits on the NHS England Specialised Cancer Surgery Clinical Reference Group to delivery commissioning of NHS Services

Dr Paul Huang is Head of the Molecular and Systems Oncology Laboratory at The Institute of Cancer Research (ICR) in London, UK. He is a tenured Faculty member and Reader in Molecular & Translational Oncology within the Division of Molecular Pathology and holds a Cancer Research UK Career Establishment Award. He received his PhD in Biological Engineering from Massachusetts Institute of Technology. His laboratory focuses on understanding aberrant signalling networks and drug resistance in sarcomas, with the goal of developing biomarkers and new therapies for these diseases.

Dr Huang is the Deputy Director of the Joint Royal Marsden-ICR Sarcoma Research Centre, one of the largest sarcoma research centres in Europe. He serves as Vice Chair of the Pathology & Translational Research Committee of the EORTC Soft Tissue and Bone Sarcoma Group and as a member of several panels including the NCRI Sarcoma Clinical Studies Group, the NCRI Cellular Molecular Pathology (CM-Path) Clinical Trial Pathology Advisory Group (CT-PAG) and Research Advisory Committee of Sarcoma UK.  He was elected a Fellow of the Royal Society of Biology in 2020.

Sophie Postel-Vinay is currently Physician Scientist at the Drug Development Department and U981 INSERM research unit of Gustave Roussy Cancer Campus, where she leads an independent research group.

She received her medical degree from the Université René Descartes Paris V in 2010, and joined the faculty in November 2013 after completion of her PhD. She completed her residency training in Paris, and spent 18 months at the Royal Marsden Hospital in London in the Drug Development Unit.

Dr Postel-Vinay is member of AACR and ASCO, from which she received a merit award in 2010. She is also an ESMO member and received the ESMO translational research fellowship for her PhD that was performed at the Institute of Cancer Research (London), focusing on DNA repair and synthetic lethality.

Her research activity focuses on chromatin remodeling and its interplay with DNA damage repair and immune modulation in solid tumor cancer models. Her research interests include DNA repair, chromatin remodeling and synthetic lethality, sarcoma, drug development, predictive biomarkers and emerging targets.

Dr Sisley is a Senior Lecturer at the Department of Oncology at the University of Sheffield with a specialisation in sarcomas and an interest in rare tumours.

Karen's research focuses on the genetic changes related to subtypes of rare tumours, and the impact that these have on tumour behaviour.

A Medical Oncologist at the London Sarcoma Service (as part of the Royal National Orthopaedic Hospital & University College London Hospital), Dr Strauss specialises in the systemic treatment of soft tissue and bone sarcomas in teenagers and adults. Her research focuses on identifying new targets for therapy in osteosarcoma and Ewing's sarcoma, as well as developing early phase clinical trials.

Sandra is also the principal investigator for a number of clinical trials and is a member of the National Cancer Research Institute Clinical Studies Group for sarcoma and bone subgroup, as well as the EORTC Soft Tissue and Bone Sarcoma Group.

A Clinical Professor at The University of Leeds and Lead Consultant in Medical Oncology, Prof. Velikova’s clinical work focuses on the systemic treatment of breast cancer patients with early and advanced disease, including chemotherapy, endocrine therapy and targeted treatments.

Her research also focuses on Quality of Life in people with breast cancer and leads the QoL sub-studies of large national and international research trials. This led to her working on the development of a crucial web-based system for collecting self-reported data into the adverse effects during and after chemotherapy and radiotherapy treatments, and integrating this with electronic patient records that generate alerts for clinicians and support immediate patient care.

Galina currently chairs the National Cancer Research Institute (NCRI) Psychology Oncology and Survivorship Clinical Studies Group and is an elected Board member of the European Organisation for Research and Treatment of Cancer (EORTC). She has previously chaired the British Psychosocial Oncology Society (BPOS) and the EORTC Quality of Life Group. 

With training at UCL and Royal Medical School, and a postgraduate in general medicine, Dr Wood now specialises as a Consultant in Palliative Medicine at The Royal Marsden and Royal Brompton Hospitals.

Jayne is also the Clinical Lead for education and the Training Programme Director for core medical trainees across The Royal Marsden.